| Phase 3 and Phase 2 Studies Show Early, Sustained Declines in Plasma p-tau217 and p-tau217/Aβ42 in APOE4 Homozygotes and Heterozygotes Treated with Oral Valiltramiprosate, Supporting Amyloid Target Engagement The post Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in APOE4 Carriers with Early Alzheimer’s Disease appeared first on Alzheon |
Preserving Future Memories . |
